BioAge Labs (BIOA) Gross Margin (2025 - 2026)
BioAge Labs' (BIOA) quarterly Gross Margin came in at 580.46% in Q2 2026, down 10189.0% year-over-year from N/an in Q2 2025, and down 55.18% quarter-over-quarter from 374.06% in Q1 2026.
Powered by 
Analysis
BioAge Labs (BIOA) Gross Margin (2025 - 2026) Analysis & Trends
BioAge Labs has disclosed Gross Margin across 2 years of filings, most recently posting 580.46% for Q2 2026.
- In Q2 2026, Gross Margin fell 10189.0% year-over-year to 580.46%; the TTM figure through Jun 2026 stood at 486.04% (up 61570.0% YoY), while the FY2025 annual figure was 449.74%, changed N/A from the prior year.
- Gross Margin came in at 580.46% for Q2 2026 at BioAge Labs, down from 374.06% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 219.02% in Q1 2025 to a low of 580.46% in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 72.04% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 79.76% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 85.33% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 91.59% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 90.43% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 35.86% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 76.90% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 71.60% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 80.31% |
| 10 | BioAge Labs | 409.83 Mn | 409.83 Mn | -14.23 Mn | -580.46% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -580.46% |
| Mar 31, 2026 | -374.06% |
| Dec 31, 2025 | -504.84% |
| Sep 30, 2025 | -496.30% |
| Jun 30, 2025 | -478.57% |
| Mar 31, 2025 | -219.02% |